Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBW-3220 vs investigator's choice in BTK-pretreated relapsed/refractory CLL/SLL
ChiCTR2500114564Phase 3Not yet recruiting
- Sponsor
- National Clinical Research Center for Hematological Disease
- Start
- Dec 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of HBW-3220 in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by National Clinical Research Center for Hematological Disease. Primary endpoint: Progression-Free Survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
HBW-3220
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ChiCTR2500114564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114564.